US FDA Diversity Action Plan And Sex Differences Webpages Restored: Will Others Follow?

A federal judge granted Doctors for America’s motion for a temporary restraining order directing the FDA and CDC to restore information removed from the agencies’ websites to comply with a presidential executive order targeting “gender ideology extremism.”

Wayback Machine
The sudden removal of information resources from federal agency websites is not excused by their availability on the Wayback Machine, a judge said. (Shutterstock)

A court order directing the US Food and Drug Administration to restore a webpage for the clinical trial diversity action plan guidance could lead to reinstatement of other information removed from the agency’s website in recent weeks.

More from Policy & Regulation

Over The Counter: What To Expect From The 61st AESGP Annual Meeting, With Jurate Švarcaite

 
• By 

HBW Insight speaks to AESGP director general Jurate Švarcaite about what's on the agenda for the upcoming 61st AESGP Annual Meeting, which will take place in Warsaw, Poland, between 2-4 June. Highlights include the role of prevention in self-care, discussions about how regulators will ensure the competitiveness of European industry on the world stage and incoming changes to sustainability legislation.

Longer ACNU Rule Review Gets Kennedy Signature

 

Notice published on 21 March is a word-for-word copy, other than different dates, of a document published on 24 January, Kennedy says the ACNU final rule’s effective date is delayed until 27 May, two months later than the initial delayed effective date.

US Monograph Facility Fees Due In Six Weeks While DOGE Subjects FDA To Rapid Changes

 

FDA’s OMUFA facility fees for FY2025, due on 2 June, increase nearly $2,400 to $37,556 for OTC monograph drug manufacturers and $2,200 to $25,037 for contract manufacturers. Overall target OMUFA fee total is just short of $36.47m, up from $32.25m for FY2024.

US FDA Questions Third-Party Labs’ Benzene Testing Methods As Acne Products Recalled

 
• By 

FDA testing of 95 benzoyl peroxide products due to concerns about elevated benzene detected by third-party testers found 90% with undetectable or extremely low benzene levels.

More from HBW Insight

Principle Relaunches Vitawell To Help Consumers Navigate UK Supplement ‘Minefield’

 
• By 

Vitawell seeking to empower consumers left confused by the vast array of dietary supplements available to them in the UK.

Some New Tools, More Old For Supplement Sector Enforcement During Trump’s Second Term

 

Tariffs on imports from China and look at eliminating self-affirmed GRAS pathway introduced under Trump while DoJ Consumer Protection Branch also continues supplement sector priorities enduring across administrations.

People On The Move: Appointments At PAGB, Activ’Inside, EMA

 
• By 

Round up of the latest appointments: PAGB names vice presidents; Activ'Inside gets first US head; EMA elects management board chair.